Literature DB >> 3428347

Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions.

V W Steinijans1, H U Schulz, A Böhm, W Beier.   

Abstract

The effect of different intravenous infusions on the absolute bioavailability of theophylline from a sustained-release formulation has been investigated. Oral administration of 750 mg theophylline (2 capsules Euphylong 375) was referenced to intravenous aminophylline infusions corresponding to 506 mg theophylline over 8 h (63 mg.h-1) in Study 1, and to 749 mg theophylline over 14 h in Study 2. A reduction in the infusion rate from 69 to 33 mg.h-1 was made in Study 2 after 8 h in order to mimic the concentration/time profile of the oral formulation as closely as possible. The absolute bioavailability was 100 (89, 115)% in Study 1 and 88 (73, 105)% in Study 2. The lower clearance values and, as a consequence, the lower bioavailability ratios observed with the higher intravenous dose, although not significant, indicate that the absolute bioavailability of theophylline might appear to depend on the choice of the intravenous reference standard.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3428347     DOI: 10.1007/BF00544248

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Intravenous digoxin as a bioavailability standard: slow infusion and rapid injection.

Authors:  D J Greenblatt; D W Duhme; J Koch-Weser; T W Smith
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

2.  Bayesian approach to bioequivalence assessment: an example.

Authors:  H Fluehler; A P Grieve; D Mandallaz; J Mau; H A Moser
Journal:  J Pharm Sci       Date:  1983-10       Impact factor: 3.534

3.  Differences in steady-state plasma levels between aminophylline and theophylline sustained-release micropellets after repeated circadian dosing.

Authors:  H U Schulz; V W Steinijans; H Gabel
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-11

4.  Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals.

Authors:  V W Steinijans; E Diletti
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Measurement of excretion characteristics of theophylline and its major metabolites.

Authors:  J H Jonkman; D Tang; R A Upton; S Riegelman
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

Authors:  S Riegelman; P Collier
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

7.  Nonlinear theophylline elimination.

Authors:  D D Tang-Liu; R L Williams; S Riegelman
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

8.  Non-linear elimination processes of theophylline.

Authors:  U Gundert-Remy; R Hildebrandt; N Hengen; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Once daily theophylline: multiple-dose comparison of an encapsulated micro-osmotic system (Euphylong) with a tablet (Uniphyllin).

Authors:  V W Steinijans; H U Schulz; W Beier; H W Radtke
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1986-08
  9 in total
  3 in total

Review 1.  Pharmacokinetic characterization of controlled-release formulations.

Authors:  V W Steinijans
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 2.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 3.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.